Novira names Christian Schade as chief executive officer

21 March 2014
novira

Novira Therapeutics has announced the appointment of Christian Schade as chief executive officer, effective March 19.

Mr Schade has more than 30 years of extensive private and public pharmaceutical and biotechnology industry experience as well as broad capital markets experience from his tenure in the investment banking industry.

Prior to joining Novira, Mr Schade was Executive Vice President and Chief Financial Officer of Omthera Pharmaceuticals where he played a lead role in taking the company public and in the sale of the company to AstraZeneca, which closed in July 2013.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical